The neurotrophic agent 'Cerebrolysin' [FPF 1070] is effective as an adjuvant treatment in patients with acute ischaemic stroke, according to results from the recent Multicenter Cerebrolysin Acute (MCA) Stroke Trial. Patients treated with 'Cerebrolysin' had improved global, motor and cognitive function compared with those receiving placebo. Furthermore, the study indicated that early initiation of neuroprotective therapy improves outcomes, and is well tolerated. The results of the MCA study were discussed in a company-sponsored satellite symposium at the 6th Congress of the European Federation of Neurological Societies (EFNS) [Vienna, Austria; October 2002].*